Type 2 diabetes patients assessment of the COMODITY12 mHealth system

Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial....

Full description

Bibliographic Details
Main Authors: Przemyslaw Kardas, Krzysztof Lewandowski
Format: Article
Language:English
Published: European Alliance for Innovation (EAI) 2015-11-01
Series:EAI Endorsed Transactions on Pervasive Health and Technology
Subjects:
Online Access:http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283
id doaj-36ec2f6c08364be691209deea09fee5a
record_format Article
spelling doaj-36ec2f6c08364be691209deea09fee5a2020-11-25T01:44:33ZengEuropean Alliance for Innovation (EAI)EAI Endorsed Transactions on Pervasive Health and Technology2411-71452015-11-01141510.4108/icst.pervasivehealth.2015.259283Type 2 diabetes patients assessment of the COMODITY12 mHealth systemPrzemyslaw Kardas0Krzysztof Lewandowski1First Department of Family Medicine, Medical University of Lodz; przemyslaw.kardas@umed.lodz.plDepartment of Endocrinology & Metabolic Diseases, Medical University of LodzBackground: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283mhealthcomodity12diabetes
collection DOAJ
language English
format Article
sources DOAJ
author Przemyslaw Kardas
Krzysztof Lewandowski
spellingShingle Przemyslaw Kardas
Krzysztof Lewandowski
Type 2 diabetes patients assessment of the COMODITY12 mHealth system
EAI Endorsed Transactions on Pervasive Health and Technology
mhealth
comodity12
diabetes
author_facet Przemyslaw Kardas
Krzysztof Lewandowski
author_sort Przemyslaw Kardas
title Type 2 diabetes patients assessment of the COMODITY12 mHealth system
title_short Type 2 diabetes patients assessment of the COMODITY12 mHealth system
title_full Type 2 diabetes patients assessment of the COMODITY12 mHealth system
title_fullStr Type 2 diabetes patients assessment of the COMODITY12 mHealth system
title_full_unstemmed Type 2 diabetes patients assessment of the COMODITY12 mHealth system
title_sort type 2 diabetes patients assessment of the comodity12 mhealth system
publisher European Alliance for Innovation (EAI)
series EAI Endorsed Transactions on Pervasive Health and Technology
issn 2411-7145
publishDate 2015-11-01
description Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.
topic mhealth
comodity12
diabetes
url http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283
work_keys_str_mv AT przemyslawkardas type2diabetespatientsassessmentofthecomodity12mhealthsystem
AT krzysztoflewandowski type2diabetespatientsassessmentofthecomodity12mhealthsystem
_version_ 1725027946620518400